February 20, 2026
Greece’s pharmaceutical supply chain entered a new compliance era in 2025. With the EU-wide Falsified Medicines Directive (FMD) framework already established, Greece had a longer transition period before the EU end-to-end verification model became fully operational domestically. That changed in early 2025.
Greece aligned national practice with Commission Delegated Regulation (EU) 2016/161 (the “Safety Features Regulation”) through Ministerial Decision Δ3(α) 6030/2025 (FEK 407/Β/07.02.2025) and a key EOF (National Organization for Medicines) circular dated 20.02.2025 (Circular No. 21036/20.02.2025). Follow-up clarifications were issued in March 2025 (Circular No. 30784/13.03.2025) to support implementation.
For companies importing, distributing, repackaging, or dispensing cannabis-derived medicines in Greece, this update is not “generic pharma news.” These products are typically prescription-only, higher scrutiny, and frequently involve cross-border supply chains—exactly the scenario where serialization, verification, and controlled repackaging are most critical.
This article explains the practical impact of Greece’s 2025 rules on:
Informational only; not legal advice.
Across the EU, prescription medicines within scope must carry two safety features:
The technical and procedural requirements are set out in Commission Delegated Regulation (EU) 2016/161.
External reference:
Greece implemented and tightened national controls via:
While the EU Regulation is directly applicable, these Greek instruments matter because they:
Official sources (Greek regulator and verification organization):
For in-scope prescription medicines, the 2D DataMatrix must include four mandatory data elements under the EU model:
HMVO summarizes these requirements and clarifies that Greece’s national reimbursement/identification number is handled via system data (not as a “fifth” DataMatrix element).
Source:
Greece participates in the broader European Medicines Verification System (EMVS) managed through the EMVO European Hub, with national verification executed via the Greek system operated by HMVO.
Source:
If your product is supplied as a regulated medicinal product (not a supplement, not a compounded preparation), and it is prescription-only and within scope, you should assume:
In other words, “Greece medical cannabis serialization 2025” is not a niche requirement—it is a core gating item for lawful release.
The anti-tampering device is not just a packaging quality feature; it is part of compliance. If the ATD is missing, damaged, or replaced incorrectly during relabeling/repackaging, downstream actors may treat the pack as suspicious.
For higher-risk categories such as cannabis-derived prescription medicines, ATD failures can cause:
Under the EU model, the person authorized to supply to the public typically:
This is the “end-to-end” protection concept: the pack’s serial cannot be reused after dispensing.
Wholesalers have defined obligations to verify authenticity under certain scenarios (risk-based and transaction-based). In some cases (e.g., certain exports or supplies to specific institutions), the unique identifier may need to be decommissioned by a wholesaler.
For Greece, the transition period created practical complexity because legacy mechanisms existed historically. EOF’s 2025 communications emphasize proper handling during the transition and real-time reporting expectations where applicable.
Reference:
For marketing authorization holders and manufacturers, the success or failure of verification downstream often traces back to upstream data integrity:
Repackaging (including covering/removing existing safety features) is a primary diversion point for falsified products. That’s why the EU framework—and Greece’s 2025 alignment—treats it as a controlled activity.
In general, when you remove/cover safety features, you risk breaking the chain of authenticity unless you follow prescribed steps.
Before removing or covering any existing safety feature, the responsible entity should ensure the pack is authenticated and handled under controlled, documented procedures—with EOF oversight expectations clearly signaled in the 2025 circular implementation messaging.
A helpful secondary discussion (industry legal analysis) summarizing Greece’s ministerial decision and EOF circulars:
Parallel trade (lawful intra-EU trade of medicines) often requires:
The EU has also issued guidance on safety features and parallel trade repackaging in the broader context.
Where cannabis-derived medicines are involved, parallel trade may be more limited in practice due to controlled-substance handling rules, prescribing restrictions, or product-specific authorization pathways. Still, the pack-level safety-feature workflow remains relevant wherever repackaging occurs.
EOF’s role as the national competent authority means inspections and investigations can focus on:
When something goes wrong—scan failures, mismatched master data, damaged ATD, unexpected decommissioned status—companies should be ready to show:
If you import cannabis-derived medicines into Greece, you need more than import permits and GDP arrangements. The pack cannot move smoothly through the lawful channel if:
Common triggers include:
If relabeling/repackaging is needed, treat it like a regulated manufacturing-quality activity with serialization controls—not as a late-stage artwork tweak.
These products often come with heightened oversight across:
Serialization adds pack-level traceability that can strengthen your compliance posture—but only if your data quality and SOPs match the operational reality.
This checklist is designed for serialization vendors, MAHs, repackagers/parallel distributors, wholesalers, and pharmacies preparing to import, release, or dispense cannabis-derived medicines in Greece.
Context source (Greece transition end date referenced by HMVO):
Greece’s 2025 shift makes serialization failures much more visible because verification happens at multiple points, especially at dispense.
Common operational “failure modes” include:
For cannabis-derived medicines, these failures can translate into:
If you are preparing to import, distribute, or repackage cannabis-derived medicines in Greece, the fastest path to readiness is a single compliance plan that connects packaging, serialization IT, GDP/GMP quality systems, and EOF/HMVO verification realities.
Use https://cannabisregulations.ai/ to track regulatory updates, build jurisdiction-specific compliance checklists, and standardize evidence packs for audits and inspections.
Greece’s pharmaceutical supply chain entered a new compliance era in 2025. With the EU-wide Falsified Medicines Directive (FMD) framework already established, Greece had a longer transition period before the EU end-to-end verification model became fully operational domestically. That changed in early 2025.
Greece aligned national practice with Commission Delegated Regulation (EU) 2016/161 (the “Safety Features Regulation”) through Ministerial Decision Δ3(α) 6030/2025 (FEK 407/Β/07.02.2025) and a key EOF (National Organization for Medicines) circular dated 20.02.2025 (Circular No. 21036/20.02.2025). Follow-up clarifications were issued in March 2025 (Circular No. 30784/13.03.2025) to support implementation.
For companies importing, distributing, repackaging, or dispensing cannabis-derived medicines in Greece, this update is not “generic pharma news.” These products are typically prescription-only, higher scrutiny, and frequently involve cross-border supply chains—exactly the scenario where serialization, verification, and controlled repackaging are most critical.
This article explains the practical impact of Greece’s 2025 rules on:
Informational only; not legal advice.
Across the EU, prescription medicines within scope must carry two safety features:
The technical and procedural requirements are set out in Commission Delegated Regulation (EU) 2016/161.
External reference:
Greece implemented and tightened national controls via:
While the EU Regulation is directly applicable, these Greek instruments matter because they:
Official sources (Greek regulator and verification organization):
For in-scope prescription medicines, the 2D DataMatrix must include four mandatory data elements under the EU model:
HMVO summarizes these requirements and clarifies that Greece’s national reimbursement/identification number is handled via system data (not as a “fifth” DataMatrix element).
Source:
Greece participates in the broader European Medicines Verification System (EMVS) managed through the EMVO European Hub, with national verification executed via the Greek system operated by HMVO.
Source:
If your product is supplied as a regulated medicinal product (not a supplement, not a compounded preparation), and it is prescription-only and within scope, you should assume:
In other words, “Greece medical cannabis serialization 2025” is not a niche requirement—it is a core gating item for lawful release.
The anti-tampering device is not just a packaging quality feature; it is part of compliance. If the ATD is missing, damaged, or replaced incorrectly during relabeling/repackaging, downstream actors may treat the pack as suspicious.
For higher-risk categories such as cannabis-derived prescription medicines, ATD failures can cause:
Under the EU model, the person authorized to supply to the public typically:
This is the “end-to-end” protection concept: the pack’s serial cannot be reused after dispensing.
Wholesalers have defined obligations to verify authenticity under certain scenarios (risk-based and transaction-based). In some cases (e.g., certain exports or supplies to specific institutions), the unique identifier may need to be decommissioned by a wholesaler.
For Greece, the transition period created practical complexity because legacy mechanisms existed historically. EOF’s 2025 communications emphasize proper handling during the transition and real-time reporting expectations where applicable.
Reference:
For marketing authorization holders and manufacturers, the success or failure of verification downstream often traces back to upstream data integrity:
Repackaging (including covering/removing existing safety features) is a primary diversion point for falsified products. That’s why the EU framework—and Greece’s 2025 alignment—treats it as a controlled activity.
In general, when you remove/cover safety features, you risk breaking the chain of authenticity unless you follow prescribed steps.
Before removing or covering any existing safety feature, the responsible entity should ensure the pack is authenticated and handled under controlled, documented procedures—with EOF oversight expectations clearly signaled in the 2025 circular implementation messaging.
A helpful secondary discussion (industry legal analysis) summarizing Greece’s ministerial decision and EOF circulars:
Parallel trade (lawful intra-EU trade of medicines) often requires:
The EU has also issued guidance on safety features and parallel trade repackaging in the broader context.
Where cannabis-derived medicines are involved, parallel trade may be more limited in practice due to controlled-substance handling rules, prescribing restrictions, or product-specific authorization pathways. Still, the pack-level safety-feature workflow remains relevant wherever repackaging occurs.
EOF’s role as the national competent authority means inspections and investigations can focus on:
When something goes wrong—scan failures, mismatched master data, damaged ATD, unexpected decommissioned status—companies should be ready to show:
If you import cannabis-derived medicines into Greece, you need more than import permits and GDP arrangements. The pack cannot move smoothly through the lawful channel if:
Common triggers include:
If relabeling/repackaging is needed, treat it like a regulated manufacturing-quality activity with serialization controls—not as a late-stage artwork tweak.
These products often come with heightened oversight across:
Serialization adds pack-level traceability that can strengthen your compliance posture—but only if your data quality and SOPs match the operational reality.
This checklist is designed for serialization vendors, MAHs, repackagers/parallel distributors, wholesalers, and pharmacies preparing to import, release, or dispense cannabis-derived medicines in Greece.
Context source (Greece transition end date referenced by HMVO):
Greece’s 2025 shift makes serialization failures much more visible because verification happens at multiple points, especially at dispense.
Common operational “failure modes” include:
For cannabis-derived medicines, these failures can translate into:
If you are preparing to import, distribute, or repackage cannabis-derived medicines in Greece, the fastest path to readiness is a single compliance plan that connects packaging, serialization IT, GDP/GMP quality systems, and EOF/HMVO verification realities.
Use https://cannabisregulations.ai/ to track regulatory updates, build jurisdiction-specific compliance checklists, and standardize evidence packs for audits and inspections.
